Resverlogix Corp. · TSX:RVX
Resverlogix — Shareholder Meeting (June 2021)
16 slides from Resverlogix's shareholder meeting presentation, Jun 22, 2021
Slide 1: Corporate Updates and Breakthroughs
TSX: RVX Resverlogix Corp. Corporate Updates and Breakthroughs AGM June 22, 2021
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends",
Slide 3: Resverlogix at a Glance
Resverlogix at a Glance • Resverlogix Corp. is a Canadian public company developing an advanced cardiovascular drug called apabetalone. We are pioneering a technology that has the ability to turn multiple disease causing genes on or off. No actual change to the human DNA occurs. Our exciting breakth
Slide 4: Health Canada Approves COVID-19 Trial
Health Canada Approves COVID-19 Trial As the result of very safe and promising data Health Canada has granted Resverlogix approval to conduct a COVID-19 clinical 4
Slide 5: Significant Apabetalone Publications – COVID-19
Significant Apabetalone Publications – COVID-19 Dual Mechanism Approach – ACE2 reduction and Cytokine Storm Calming 5
Slide 6: Number of US Deaths Due to Current Diseases in 2020
Number of US Deaths Due to Current Diseases in 2020 Posted on CNN - Dec. 2020 – AGM Slide 6
Slide 7: Number of US Deaths Due to Current Diseases in 2020
Number of US Deaths Due to Current Diseases in 2020 COVID-19 Updated to June 2021 600k COVID-19 deaths 7
Slide 8: COVID-19 Clinical Trial Launch - 2021
COVID-19 CLINICAL TRIAL LAUNCH - 2021 Resverlogix’ First Short Term Revenue Potential Emergency supply, A larger Phase 3 Phase 3 should manufacturing & Health Canada trial will launch be faster than partnership agreements Trial Approval & in the USA later vaccine trials can commence during Long term
Slide 9: EVERSANA Complete Commercialization
EVERSANA™ COMPLETE COMMERCIALIZATION Patient Services End-to-end commercial strategy, operational excellence and a Channel & Field success share delivery model: 3PL Solutions Minimize financial exposure Agency Pricing Intel Services & Analytics Keep revenues Maintain full ownership Market Data
Slide 10: Adding more strength for clients every day
Adding more strength for clients every day 100% of the Top 25 Bio-pharma Companies 570 500 MDs, RNs, Life Science PharmDs Clients 3,500~ 80 100 Employees Countries Therapeutic Served Areas 25~ 25 Locations Patient Service Programs 150 Brands
Slide 11: Lead Program Also Advancing
Lead Program Also Advancing 11
Slide 12: FDA Approves Breakthrough Therapy Designation
FDA Approves Breakthrough Therapy Designation “A breakthrough therapy designation is for a drug that treats a serious or life- threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over availabl
Slide 13: Efficacy - The Drug Works! Trials confirmed a highly significant reduction
Efficacy - The Drug Works! Trials confirmed a highly significant reduction in Death, Heart Attacks and CHF Placebo 25 + Top Standard ofPlacebo Care + Top Standard of Care Hazard Ratio Ratio == 0.37 0.37 (95% • The effect of the co-administration of 20 Hazard (95%CI. CI;0.22 0.22–-0.62) 0.62) Cumulat
Slide 14: Kaplan-Meier Estimates by CKD/Non-CKD for MACE
Kaplan-Meier Estimates by CKD/Non-CKD for MACE Apabetalone Compared to Placebo CKD Group (eGFR < 60) Apabetalone + Top Standard of Care CKD Group (eGFR<60) Placebo + Top Standard of Care Placebo Events - 35/164 (21.3%) Apabetalone Events - 13/124 (10.5%) Hazard Ratio = 0.50 [95%CIs: 0.26,0.96; p=0.0
Slide 15: Targeted - Global Development Plan
TARGETED - GLOBAL DEVELOPMENT PLAN Planning details between Resverlogix and various potential partners Interim analysis Pending interim success Targeted Patient of 300 targeted FDA approval is possible enrollment should enrollment will patient events due to the Breakthrough be completed 4 start H2 2
Slide 16: Resverlogix 12 Month Key Milestones
Resverlogix 12 Month Key Milestones October April 12MM USD conversion of debenture; American Society of June Entered into $10MM USD definitive Nephrology published FDA confirms key stock purchase agreement April very positive kidney data aspects of Health Canada November regarding apabetalone BETonM